JP2017504321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504321A5 JP2017504321A5 JP2016541720A JP2016541720A JP2017504321A5 JP 2017504321 A5 JP2017504321 A5 JP 2017504321A5 JP 2016541720 A JP2016541720 A JP 2016541720A JP 2016541720 A JP2016541720 A JP 2016541720A JP 2017504321 A5 JP2017504321 A5 JP 2017504321A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- chain variable
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 78
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 26
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 24
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 24
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 24
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 24
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 206010036595 Premature delivery Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927819P | 2014-01-15 | 2014-01-15 | |
| US61/927,819 | 2014-01-15 | ||
| PCT/US2015/011391 WO2015108967A2 (en) | 2014-01-15 | 2015-01-14 | Rsv-specific antibodies and functional parts thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020020602A Division JP2020103293A (ja) | 2014-01-15 | 2020-02-10 | Ｒｓｖ特異的抗体およびその機能的部分 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504321A JP2017504321A (ja) | 2017-02-09 |
| JP2017504321A5 true JP2017504321A5 (enExample) | 2018-02-22 |
| JP6836398B2 JP6836398B2 (ja) | 2021-03-03 |
Family
ID=53543612
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541720A Active JP6836398B2 (ja) | 2014-01-15 | 2015-01-14 | Ｒｓｖ特異的抗体およびその機能的部分 |
| JP2020020602A Pending JP2020103293A (ja) | 2014-01-15 | 2020-02-10 | Ｒｓｖ特異的抗体およびその機能的部分 |
| JP2023010903A Pending JP2023052693A (ja) | 2014-01-15 | 2023-01-27 | Ｒｓｖ特異的抗体およびその機能的部分 |
| JP2025003702A Pending JP2025063143A (ja) | 2014-01-15 | 2025-01-09 | Ｒｓｖ特異的抗体およびその機能的部分 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020020602A Pending JP2020103293A (ja) | 2014-01-15 | 2020-02-10 | Ｒｓｖ特異的抗体およびその機能的部分 |
| JP2023010903A Pending JP2023052693A (ja) | 2014-01-15 | 2023-01-27 | Ｒｓｖ特異的抗体およびその機能的部分 |
| JP2025003702A Pending JP2025063143A (ja) | 2014-01-15 | 2025-01-09 | Ｒｓｖ特異的抗体およびその機能的部分 |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US20160340414A1 (enExample) |
| EP (3) | EP4353316A3 (enExample) |
| JP (4) | JP6836398B2 (enExample) |
| KR (1) | KR102188437B1 (enExample) |
| CN (2) | CN105916520A (enExample) |
| AU (4) | AU2015206570A1 (enExample) |
| CA (1) | CA2933200C (enExample) |
| CY (2) | CY1123425T1 (enExample) |
| DK (1) | DK3094353T3 (enExample) |
| ES (1) | ES2795727T3 (enExample) |
| FI (1) | FIC20230016I1 (enExample) |
| FR (1) | FR23C1016I1 (enExample) |
| HR (1) | HRP20200607T1 (enExample) |
| HU (2) | HUE048855T2 (enExample) |
| LT (2) | LT3094353T (enExample) |
| LU (1) | LUC00305I2 (enExample) |
| MX (1) | MX374517B (enExample) |
| NL (1) | NL301228I2 (enExample) |
| NO (1) | NO2023016I1 (enExample) |
| PL (1) | PL3094353T3 (enExample) |
| PT (1) | PT3094353T (enExample) |
| RS (1) | RS60387B1 (enExample) |
| SI (1) | SI3094353T1 (enExample) |
| SM (1) | SMT202000282T1 (enExample) |
| TW (1) | TWI705974B (enExample) |
| WO (1) | WO2015108967A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
| US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| WO2019152600A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against respiratory syncytial virus |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| US12024553B2 (en) | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| EP4402166A2 (en) | 2021-09-13 | 2024-07-24 | MedImmune Limited | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
| CN116987183B (zh) * | 2022-07-22 | 2024-10-15 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JP2008518936A (ja) * | 2004-10-29 | 2008-06-05 | メディミューン，インコーポレーテッド | Ｒｓｖ感染症および関連状態を予防および治療する方法 |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| CN101679513A (zh) | 2007-03-06 | 2010-03-24 | 西福根有限公司 | 用于治疗呼吸道合胞病毒感染的重组抗体 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| AU2008268362A1 (en) | 2007-06-26 | 2008-12-31 | Medimmune, Llc | Methods of treating RSV infections and related conditions |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| EP2240581B1 (en) | 2008-01-15 | 2016-05-11 | AbbVie Inc. | Improved mammalian expression vectors and uses thereof |
| ES2666584T3 (es) * | 2009-07-15 | 2018-05-07 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| CA2776249C (en) | 2009-10-06 | 2021-01-19 | Medimmune Ltd | Rsv-specific binding molecule |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| US20120263715A1 (en) | 2009-10-28 | 2012-10-18 | Medimmune, Llc | Topical Methods Of Treating RSV Infections And Related Conditions |
| EP2825191B1 (en) | 2012-03-16 | 2019-08-28 | University Health Network | Soluble toso protein and its use in treating autoimmune disorders |
| IN2014DN09951A (enExample) * | 2012-05-22 | 2015-08-14 | Shire Human Genetic Therapies | |
| DK2950886T3 (da) | 2013-02-01 | 2020-03-23 | Medimmune Llc | Respiratorisk syncytialvirus-f-protein-epitoper |
| SI3094353T1 (sl) | 2014-01-15 | 2020-07-31 | Medimmune, Llc | RSY-specifična protitelesa in njihovi funkcionalni deli |
| EP3589318A1 (en) | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
| TW202228779A (zh) | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2015
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Active
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en not_active Ceased
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 MX MX2016008639A patent/MX374517B/es active IP Right Grant
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 CA CA2933200A patent/CA2933200C/en active Active
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
-
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
-
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
-
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
-
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 FR FR23C1016C patent/FR23C1016I1/fr active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-25 CY CY2023011C patent/CY2023011I2/el unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-27 LU LU00305C patent/LUC00305I2/fr unknown
- 2023-04-28 LT LTPA2023514C patent/LTC3094353I2/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown
-
2024
- 2024-11-11 US US18/943,007 patent/US20250179153A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003702A patent/JP2025063143A/ja active Pending
- 2025-02-14 AU AU2025201056A patent/AU2025201056A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504321A5 (enExample) | ||
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2010536384A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2011509245A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2018527919A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2017531642A5 (enExample) | ||
| JP2017522903A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2014533239A5 (enExample) | ||
| JP2017522043A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2017529097A5 (enExample) | ||
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2012525829A5 (enExample) | ||
| HRP20190714T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| JP2011528901A5 (enExample) |